Insmed (INSM) Other Non-Current Assets (2011 - 2026)
Insmed (INSM) posted quarterly Other Non-Current Assets of $99.3 million for Q1 2026, up 10.6% year-over-year from $89.8 million in Q1 2025, and up 1.95% quarter-over-quarter from $97.4 million in Q4 2025.
Insmed (INSM) Other Non-Current Assets (2011 - 2026) Analysis & Trends
Insmed's Other Non-Current Assets history runs 16 years deep, the most recent figure standing at $99.3 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 10.6% year-over-year to $99.3 million; the TTM figure through Mar 2026 stood at $99.3 million (up 10.6% YoY), while the FY2025 annual figure was $97.4 million, up 4.45% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $99.3 million, up from $97.4 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $99.3 million in Q1 2026, with the low at $57.2 million in Q1 2022.
- The 5-year median for Other Non-Current Assets is $89.8 million (2025), against an average of $85.6 million.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets jumped 49.25% in 2022, then fell 6.21% in 2025.
- Insmed's Other Non-Current Assets stood at $76.1 million in 2022, then rose by 26.9% to $96.6 million in 2023, then decreased by 3.47% to $93.2 million in 2024, then rose by 4.45% to $97.4 million in 2025, then grew by 1.95% to $99.3 million in 2026.
- Business Quant data shows INSM's Other Non-Current Assets at $99.3 million in Q1 2026, $97.4 million in Q4 2025, and $91.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 29.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 104.44 Mn |
| Mar 31, 2026 | 99.28 Mn |
| Dec 31, 2025 | 97.38 Mn |
| Sep 30, 2025 | 91.61 Mn |
| Jun 30, 2025 | 88.81 Mn |
| Mar 31, 2025 | 89.76 Mn |
| Dec 31, 2024 | 93.23 Mn |
| Sep 30, 2024 | 96.86 Mn |
| Jun 30, 2024 | 85.83 Mn |
| Mar 31, 2024 | 95.70 Mn |
| Dec 31, 2023 | 96.57 Mn |
| Sep 30, 2023 | 92.49 Mn |
| Jun 30, 2023 | 83.45 Mn |
| Mar 31, 2023 | 81.32 Mn |
| Dec 31, 2022 | 76.10 Mn |
| Sep 30, 2022 | 63.71 Mn |
| Jun 30, 2022 | 66.30 Mn |
| Mar 31, 2022 | 57.20 Mn |
| Dec 31, 2021 | 50.99 Mn |
| Sep 30, 2021 | 47.60 Mn |